A new prognostic factor in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan: Hemoglobin, albumin, lymphocytes and platelets (HALP) score

Authors : Mustafa KORKMAZ, Melek KARAKURT ERYILMAZ, Mehmet Zahid KOÇAK, Aykut DEMİRKIRAN, Murat ARAZ, Mustafa KARAAĞAÇ, Mehmet ARTAÇ

Pages : 19-23

Doi:10.47482/acmr.1175461

View : 17 | Download : 6

Publication Date : 2023-01-31

Article Type : Research Paper

Abstract :Background: We aimed to investigate whether the HALP score is a prognostic marker in patients with recurrent GBM who were given bevacizumab plus irinotecan. Methods: We compared the survival of patients followed up in our clinic with the diagnosis of recurrent GBM and treated with bevacizumab plus irinotecan, according to HALP score. Results: Median PFS and OS were 4.5 insert ignore into journalissuearticles values(0.9-14.9); and 8 insert ignore into journalissuearticles values(0.9-21.3); months, respectively. The median PFS of the low HALP score group was 1.85 insert ignore into journalissuearticles values(1.3-3.37); months, and of the high HALP score group was 4.96 insert ignore into journalissuearticles values(0.9-14.9); months insert ignore into journalissuearticles values(p=0.03);. The OS of the high HALP score group insert ignore into journalissuearticles values(9.63 [7.28-11.9]); was statistically higher compared with low HALP score group insert ignore into journalissuearticles values(2.26 [0.88-3.65]); insert ignore into journalissuearticles values(p<0.001);. In univariate analysis HALP score was a significant prognostic factor; patients with low HALP score had a poorer prognosis than high HALP score insert ignore into journalissuearticles values(HR: 0.063, p<0.001);. The multivariate analysis showed that HALP score insert ignore into journalissuearticles values(p=0.003);, and residual tumor insert ignore into journalissuearticles values(p=0.029); were significant prognostic factors. In multivariate Cox regression analysis, low HALP score was a significant poor prognostic factor for OS compared with high HALP score insert ignore into journalissuearticles values(HR: 0.063, p<0.001);. Conclusions: We showed that the HALP score at the start of treatment is an independent prognostic factor for PFS and OS in patients with recurrent GBM treated with bevacizumab plus irinotecan. The HALP score, which can be easily calculated by routine tests before chemotherapy, can be used as a pognostic marker for bevacizumab treatment decision.
Keywords : Bevacizumab, Glioblastoma multiforme, HALP, Prognostic marker